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Purpose: The improvement of physical activity in patients with COPD is an important
issue. However, no standard for the recommended number of steps for patients with COPD
has been determined. We conducted a retrospective observational study to create a simple
standard equation for the daily step count, which makes it easier to determine whether each
subject is attaining his/her predicted value or not.
Patients and methods: Stable outpatients diagnosed with COPD whose physical activities
had been measured using a triaxial accelerometer for more than 2 weeks were recruited from
5 institutes in Japan. Factors associated with the step count were detected by multivariate
regression analysis. After the data were transformed to a normalized distribution, a multi-
variate linear regression equation was created using stepwise regression.
Results: One hundred sixty-two patients aged 72.3 (7.2) years and of FEV1 %pred 59.2
(22.8) % were recruited. Among the parameters, age, mMRC dyspnea scale and inspiratory
capacity (IC) were detected by the stepwise method. The created standard equation was
“Step count = (−0.079×[age]−1.595×[mMRC]+2.078×[IC]+18.149)3”. The correlations
between the calculated values and the measured values were observed, and fixed, and
proportional biases between them were also observed. When patients with <6500 steps/day
were selected, no systematic bias between them could be detected.
Conclusion: A simple standard equation for Japanese patients with COPD was created
using age, mMRC and IC, and could provide an individual-predicted value, especially for
patients with <6500 steps/day.
Keywords: COPD, physical activity, behavior modification, goal setting, accelerometer
Plain language summary
A simple standard equation for step count in Japanese patients with COPD was created using
age, mMRC and IC. This could become helpful to determine whether each subject is
attaining his/her predicted value or not.
Introduction
Physical activity (PA) in patients with COPD is decreased compared to that in healthy
subjects.1,2 Reduced PA is associated with mortality3–5 and is the greatest risk factor
of COPD mortality.4 Therefore, the importance of maintenance and improvement of
the PA in patients with COPD has been receiving increased attention.
Though the effects of several interventions such as bronchodilators,6–10
rehabilitation,11–13 or counseling14 on the PA in patients with COPD are still
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controversial, larger improvement in PA tended to be
observed with counseling than with bronchodilators or
rehabilitation.15 It has been suggested that counseling
should include a goal-setting, an improved motivation,
and a feedback.16
The American College of Sports Medicine and the
American Heart Association have recommended moder-
ate-intensity aerobic PA for a minimum of 30 mins on 5
days each week for the general population aged 65 years
or over.17 However, the recommended step count for
patients with COPD has not been determined. As PA is
restricted due to decreased pulmonary function and other
factors in patients with COPD,18 a goal equivalent to that
for healthy subjects might be excessive. The recommended
value should be decided based on the predicted value of
steps in each COPD patient. Therefore, it is necessary to
determine the predicted value of steps in each patient with
COPD, which makes it easier to determine whether each
subject is attaining his/her predicted value or not.
The aim of this study was to produce a simple standard
equation for the daily step count using some factors that
influence PA in Japanese patients with COPD.
Subjects and methods
Subjects
All stable outpatients with COPD whose physical activ-
ities had been measured using a triaxial accelerometer for
more than 2 weeks and whose post-bronchodilator spiro-
metry and mMRC dyspnea scale were evaluated within the
past 3 months based on PA assessment with written
informed consent from October 2009 to December 2017
at National Hospital Organization (NHO) Fukuoka
Hospital, Wakayama Medical University, Tohoku
University, NHO Wakayama Hospital, or NHO
Asahikawa Medical Center were retrospectively recruited.
COPD was diagnosed as a post-bronchodilator FEV1/
FVC <0.7. Patients were excluded if they had clinically
evident bronchial asthma or bronchiectasis, an exacerbation
in the past 4 weeks, factors that obviously influenced their
PA such as trauma and lower limb paralysis, decreased
cognitive function, received rehabilitation program, or
been judged inappropriate to register by a physician.
Study protocol
The step count was measured using an Actimarker (AM;
Panasonic, Osaka Japan) at Wakayama Medical University,
Tohoku University, NHO Wakayama Hospital, and NHO
Asahikawa Medical Center, and was measured using an
active style Pro HJA-350 (HJA-350; OMRON, Kyoto
Japan) at NHO Fukuoka Hospital. Participants were
required to wear the accelerometer for 24 hrs excluding
bathing time. The reproducibility between the step count
measured by AM and those by active style Pro HJA-750C
(HJA-750C; OMRON), which was programed with the
same algorism as that for the HJA-350, was evaluated by
wearing both devices at the same time for 1 week
(Table S1, Figure S1). Both AM and HJA-750C were
already validated for evaluating PA in patients with
COPD.19,20
From among the analyzing parameters including
anthropometric data, symptoms, and the values of the
respiratory function test, the factors associated with the
step count were extracted. Then, a standard equation for
the step count was created. This study has been approved
by the ethics committee of Wakayama Medical University
(approval number 2131, October 4, 2017) and also the
ethics committee of each cooperative facility and has
been registered with the University Hospital Medical
Information Network (UMIN000029518, October 12,
2017). The contents of this study and the opportunity to
reject the agreement were explained on the website of
Third Department of Internal Medicine, Wakayama
Medical University.
Evaluation of measured step count
From among the measured 2 weeks, the first and last days,
holidays and rainy days, and days with monitoring for <8
hrs were excluded, and the mean value of the data
extracted from the remaining at least 3 days was employed
as the representative step count of each patient. The reason
for these exclusions was that data of the whole day were
not obtained on the first and last days, and that the PA on
rainy days decreases19,20 and that PA on holidays tended to
decrease.21,22 More than 8 or 10 hrs of monitoring time
were recommended in previous reports.23 The reproduci-
bility of PA measured by AM or HJA-750C with at least
3-day monitoring has been confirmed.19,20 The data of
subjects who had <3 valid days of measuring were
excluded.
Analyzing parameters
Age, gender, body mass index (BMI), FEV1% of predicted
(FEV1%pred), FVC % of predicted (FVC %pred), inspira-
tory capacity (IC) and mMRC dyspnea scale were
employed for evaluating associations with the step count.
Nakanishi et al Dovepress
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Respiratory function test
Spirometry was performed in the post-bronchodilator con-
dition. CHESTAC-8800, 8900 or 9800 (CHEST, Tokyo,
Japan) which measure volume signal were used at NHO
Fukuoka Hospital, Wakayama Medical University, Tohoku
University and NHO Wakayama Hospital, and DISCOM-
21 FXII (CHEST) which measures flow signal was used at
NHO Asahikawa Medical Center.
Statistical analysis
The statistical analysis was performed using GraphPad Prism
5 (GraphPad Software, San Diego, CA, USA) and IBM SPSS
Statistics (IBM Japan, Tokyo, Japan). D’Agostino-Pearson
test was used for the evaluation of a normal distribution.
Univariate regression analysis and multivariate regression
analysis were used to evaluate the correlation between the
step count and analyzed parameters. The Box-Cox transfor-
mation was used for normalizing the distribution of the step
count values. Stepwise regression was used for creating the
multivariate linear regression equation for the step count
values. Linear regression analysis and Bland–Altman plots
were used for comparisons between the measured and calcu-
lated step counts. The level of statistical significance was
considered as P<0.05.
Based on a previous report about the correlation coef-
ficient between the duration of PA and mMRC (r=0.313),2
when we set alpha as 0.05 (two-sided), beta as 0.10 and
the expected dropout rate as 20%, the required sample size
was 142, respectively. Therefore, we decided to require
more than 142 subjects for this study.
Results
One hundred sixty-two COPD patients aged 72.3 (7.2)
years and with FEV1%pred 59.2 (22.8) % (59 at NHO
Fukuoka Hospital, 46 at Wakayama Medical University,
35 at Tohoku University, 12 at NHO Wakayama Hospital,
10 at NHO Asahikawa Medical Center) were recruited
(Table 1). The reproducibility between AM and
HJA-750C was evaluated for 12 stable outpatients with
COPD aged 76.6 (6.9) years and with FEV1%pred 57.6
(18.6) % (Table S1). As the data from 3 days in each patient
were monitored, in total 36 sets of data were evaluated. The
correlation between the step counts measured by AM and
those measured by HJA-750C was statistically significant
(r=0.990, P<0.0001) by linear regression analysis
(Figure S1A). Furthermore, there was no systematic bias
and the reproducibility was confirmed by Bland–Altman
plot (mean of difference 95% CI: −30.23 to 131.43, limit









Age (years) 72.3 (7.2) 73.6 (7.0) 71.6 (7.1) 69.0 (7.2) 76.6 (6.9) 74.8 (5.4)
Gender (M/F), n 150/12 52/7 44/2 34/1 11/1 9/1
Smoking history
Pack-years 59.0 (34.0) 46.5 (24.9) 66.0 (35.6) 62.0 (33.2) 88.1 (53.1) 55.9 (18.6)
Curr/ex/non, n 25/134/3 9/48/2 10/36/0 0/35/0 4/7/1 2/8/0
BMI 21.5 (3.4) 22.1 (3.9) 21.2 (3.5) 21.4 (2.6) 19.9 (2.5) 21.7 (2.7)
GOLD stage (I/II/III/IV), n 29/72/44/17 14/23/13/9 6/23/11/6 6/16/11/2 1/5/6/0 2/5/3/0
mMRC scale (0/1/2/3/4), n 35/58/34/25/10 10/23/13/7/6 13/17/8/7/1 10/12/9/3/1 1/4/1/6/0 1/2/3/2/2
Pulmonary function
IC (L) 2.03 (0.50) 2.01 (0.60) 2.03 (0.44) 2.14 (0.46) 1.90 (0.40) 1.89 (0.35)
FVC (L) 3.13 (0.73) 2.99 (0.78) 3.34 (0.59) 3.20 (0.86) 2.78 (0.60) 3.11 (0.50)
FVC % of predicted (%) 94.8 (19.1) 95.4 (21.7) 97.5 (12.8) 90.9 (21.5) 86.1 (20.4) 103.4 (9.59)
FEV1 (L) 1.54 (0.63) 1.53 (0.71) 1.56 (0.57) 1.69 (0.63) 1.43 (0.37) 1.20 (0.49)
FEV1/FVC (%) 48.5 (13.5) 49.5 (14.6) 46.0 (13.8) 51.8 (10.7) 51.7 (9.15) 38.5 (13.3)
FEV1% of predicted (%) 59.2 (22.8) 61.7 (27.6) 56.6 (19.5) 58.9 (20.1) 57.6 (18.6) 60.1 (21.8)
Note: Data are presented as mean (SD).
Abbreviations: M, male; F, female; curr, current smoker; ex, ex-smoker; non, non-smoker; BMI, Body Mass Index; IC, inspiratory capacity; NHO Fukuoka, NHO Fukuoka
Hospital; Wakayama MU, Wakayama Medical University; Tohoku U, Tohoku University; NHO Wakayama, NHO Wakayama Hospital; NHO Asahikawa, NHO Asahikawa
Medical Center; NHO, National Hospital Organization.
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of agreement: −417.6 to 518.9) (Figure S1B). The step
count was significantly correlated with age, BMI, mMRC
scale, IC, FVC %pred and FEV1%pred with univariate
regression analysis (Table 2, Figure 1), and correlated
with age and mMRC with multivariate regression analysis
(Table 2). As the measured step counts were not normally
distributed (Figure 2), data were transformed to a normal
distribution with Box-Cox transformation (λ=0.33) in order
to create the multiple linear regression equation. When the
stepwise method was employed, age, mMRC and IC were
extracted from among the analyzed parameters, a linear
regression equation of the transformed step count was cre-
ated with those 3 parameters as independent variables. The
equation for the untransformed step count was reconstituted
from the equation for the transformed step count:
Step count ¼ ð0:079 ½age1:595 ½mMRC
þ2:078 ½IC þ 18:149Þ3
Correlation between the measured data and calculated data
was observed by linear regression analysis (r=0.470,
P<0.0001), but there was a fixed bias (mean of difference
95% CI: 0.1163–1816.2, limit of agreement: −4909 to 6726)
and a proportional bias between the two sets of data (Figure 3).
When only patients with <6500 of measured step count were
selected, 121 patients among 162 were extracted. Correlation
between the two sets of data was observed (r=0.435,
P<0.0001), and there was no fixed bias (mean of difference
95% CI: −773.32 to 0.06537, limit of agreement: −3908.7 to
3135.5) and no proportional bias between them as determined
by the Bland–Altman plot (Figure 4).
Discussion
From retrospective data, we demonstrated that the step
count was associated with age and mMRC using multi-
variate linear regression analysis. By using age, mMRC
and IC, which were extracted by a stepwise method as
independent variables, we could create a standard equation
for the step count in Japanese patients with COPD.
Table 2 Univariate and multivariate regression analysis of step
count
Variables Univariate Multivariate
r P-value β P-value
Age −0.280 <0.001 −0.209 0.008
Gender 0.085 0.280 0.023 0.769
BMI 0.163 0.038 0.034 0.647
mMRC scale −0.422 <0.001 −0.271 0.001
IC (L) 0.342 <0.001 0.111 0.257
FVC % predicted (%) 0.262 <0.001 0.003 0.974
FEV1% predicted (%) 0.328 <0.001 0.134 0.248
Abbreviations: r, correlation coefficient; β, standardized partial regression coeffi-
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Figure 1 Correlations between step count and associated variables: (A) age, (B) mMRC, (C) IC, and (D) FEV1%pred.
Abbreviations: mMRC, mMRC dyspnea scale; IC, inspiratory capacity; FEV1%pred, FEV % of predicted.
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With a univariate linear regression analysis, the step
count was associated with age, BMI, mMRC, IC, FVC and
FEV1. PA in patients with COPD has been shown to be
associated with age24 and dyspnea.22,24–26 PA has also
been shown to be associated with FEV11,22,25,27 and
FVC,1,27 but these associations were weak-to-moderate.
We have previously reported that PA was associated with
FVC, FEV1, mMRC and age,2 and that mMRC ≥2 was the
cut off value for detecting patients with low PA.28 All of
these reports are compatible with the current results.
Concerning pulmonary function, IC but not FEV1 was
detected by stepwise method as a factor influencing the
step count in the current study. Sounders et al.29 reported
meta-analyses for factors associated with steps/day in
patients with COPD. They found that the only variable
associated with steps/day after adjustment for covariates
by multivariate meta-regression was FEV1%pred, which
was not compatible with our results. In their report, how-
ever, among the values of pulmonary function, only
FEV1%pred was employed for analysis and IC was not
evaluated. Lahaije et al.30 reported that both resting IC/
total lung capacity and dynamic hyperinflation uniquely
contributed to PA in patients with COPD but FEV1%pred
did not, which supports our results. IC might influence the
step count more than FEV1 in patients with COPD.
The average step count of 46 countries obtained from the
data of Apple iPhone smartphone users of the Azumio Argus
application, was 4961 steps per day. Among the 46 countries,
Japan showed a relatively high step count (5800 –5900
steps).31 Ministry of Health, Labor and Welfare of Japan
reported that the average step count of general population
aged 20 to 64 was 7636 in males and 6657 in females, and
that of aged 65 or over was 5597 in males and 4726 in
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Figure 3 Correlation between measured and calculated step count: (A) scatter plot, r=0.470, P<0.0001 and (B) Bland–Altman plot. There were fixed and proportional biases
(mean of difference 95% CI: 0.1163–1816.2, limit of agreement: −4909 to 6726). Broken lines indicate mean difference 95% CI and dotted lines indicate limit of agreement.
Dovepress Nakanishi et al




















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
20 to 64 was 9000 in males and 8500 in females, and for aged
65 or over was 7000 in males and 6000 in females.33
However, as the exercise capacity is obviously low in
COPD compared to healthy subjects, such a large number
of steps could overburden patients with COPD. The optimal-
recommended step count for patients with COPD should be
determined based on the predicted value of steps calculated
together with associated factors. This newly developed sim-
ple standard equation could provide a predicted step count
for each patient with COPD.
The measured number of steps for COPD patients varied
among the reports, and meta-analysis of 38 papers showed
that the pooled mean estimate of steps in COPD was
4579.28. Only one Japanese report was included in this
meta-analysis, and the average step count was 6241.3.34
The step count of Japanese patients with COPD might be
relatively higher compared to other countries. Furthermore,
Japanese patients with COPD were reported to be relatively
older,35 milder stage,36–38 and have fewer exacerbations36,39
than those in other countries. As PA is influenced by several
factors including regional customs, economic condition and
environment, the recommended step count might ideally be
set separately in each country.
In our study, there were fixed and proportional biases
between the measured and calculated step counts. The step
count could be low in the most of patients but might be
relatively high and sometimes very high in some patients
with COPD. Actually, 41 patients (25.3%) walked more
than 6500 steps, which is the mean value of recommended
steps for both genders aged 65 or over.33 Especially, one
woman who was a hard-working farmer aged 75 years,
with 71.7% of FEV1%pred and mMRC 0, walked 19060
steps. The PA in such patients is sufficient and further
encouragement to improve their PA is not necessary.
When only patients with step counts of <6500 were
selected, neither fixed nor proportional biases between
the measured and calculated step counts could be detected
in the Bland–Altman plot. The presence of the few patients
with high step counts might have caused the biases; there-
fore, our newly developed equation might be useful for
patients with step counts of <6500.
There are two types of sensors which detect the step
count, the pendulum and accelerometer, and the worn parts
differ among devices. As both AM and HJA-350 are
accelerometers worn on the waist, differences in the data
from the two types of devices would likely be small. In
order to confirm the reproducibility of both devices, the
data from AM and those from HJA-750C, which was
programed with same algorism as that for the HJA-350,
were compared. Data from both devices were significantly
correlated by regression analysis and there was no sys-
tematic bias in the Bland–Altman plots (Figure S1), which
indicated the obtained data were reproducible and could be
evaluated together.
The step count is a parameter of PA, but it does not
reflect the intensity of activity. In patients with COPD with
FEV1%pred <50%, the risk of hospitalization decreases as
step count increases when the patients’ mean intensities of
PA are low (<2.7 metabolic equivalents). On the other
hand, the risk of hospitalization increases as the step
count increases when their mean intensities are high
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Figure 4 Correlation between measured and calculated step counts in patients with <6500 steps: (A) scatter plot, r=0.435, P<0.0001 and (B) Bland–Altman plot. There was
no systematic bias. (mean of difference 95% CI: −773.32 to 0.06537, limit of agreement: −3908.7 to 3135.5). Broken lines indicate mean difference 95% CI and dotted lines
indicate limit of agreement.
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an increased step count with light intensity should be
recommended for patients with severe or very severe
COPD. As not only the step count but also the intensity
of activity could be important, the mean intensity of activ-
ity should be taken into account when the calculated step
count is employed for goal setting.
There are several limitations which should be addressed.
First, the number of recruited female patients was small (only
12 patients). As gender was not associated with the step count
when analyzed as a dependent variable, both genders were
included in the same equation in the current study. A larger
number of patients might require two equations performed
separately for each gender. Second, the factors associated
with the step count were evaluated with only age, gender,
BMI, mMRC and the data of spirometry as dependent vari-
ables, but other factors were not evaluated. Many other factors
including exercise capacity, muscle strength, diffusing capa-
city, comorbidities, mental status, occupations, and environ-
mental factors are presumed to influence the step count.
Therefore, although the obtained equation might not be very
precise, but somewhat rough, this could provide a simple
standard step count for patients with COPD using easily
obtained variables in the clinical setting. Further study is
required to create a more precise equation of the step count
using other factors. Third, the step count was not evaluated by
a single accelerometer but two types of accelerometers, AM
and HJA-350C. Though the reproducibility of the 2 devices
was confirmed, ideally, it is better to measure with a single
device to completely exclude a measuring bias. Fourth, the
measured step count showed a non-normal distribution. The
process of normalization with the Box-Cox transformation
was required for employing the multiple regression equation,
which made the final equation somehow complex. Many
patients demonstrated low step counts but some patients
demonstrated high step counts, probably according to their
individual circumstances. This tendency may have caused a
non-normal distribution of the step counts. Fifth, we excluded
the data of holidays. As the inclusion or exclusion of holidays
is still controversial, the necessity of the data of holidaysmight
be evaluated in another study. Sixth, this was a retrospective
study and the data were obtained from several institutes and
with different spirometers. These conditions might have
induced biases in the step count. A further prospective study
will be needed. Seventh, since this developed equation has not
been validated in other groups of COPD subjects, it should be
confirmed in a future study.
In conclusion, a simple standard equation for the step
count in Japanese patients with COPD was created using
age, mMRC and IC. This equation could provide the
predicted value of steps in individual patients, especially
for patients with <6500 steps/day.
Ethics approval and informed
consent
This study has been approved by the ethics committee of
Wakayama Medical University (approval number 2131,
October 4, 2017) and also the ethics committee of each
cooperative facility and has been registered with the
University Hospital Medical Information Network
(UMIN000029518, October 12, 2017). Written informed
consent had been obtained from each patient at each insti-
tute. The contents of this study and the opportunity to
reject the agreement were explained on the website of
Third Department of Internal Medicine, Wakayama
Medical University.
Data sharing statement
The clinical study data used to support the findings of this
study are available from the corresponding author upon
request.
Abbreviations
NHO, National Hospital Organization; AM, Actimarker;
HJA-350, active style pro HJA-350; HJA-750C, active
style pro HJA-750C; PA, physical activity; BMI, body
mass index; IC, inspiratory capacity
Acknowledgments
The authors thank Mr Brent Bell for proof reading the
manuscript. This study was commissioned and supported
by the Environmental Restoration and Conservation
Agency of Japan.
Author contributions
All authors contributed to data analysis, drafting and revis-
ing the article, gave final approval of the version to be
published, and agree to be accountable for all aspects of
the work.
Disclosure
YM received lecturer fee from Nippon Boehringer
Ingelheim. The authors report no other conflicts of interest
in this work.
Dovepress Nakanishi et al




















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
References
1. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink
R. Characteristics of physical activities in daily life in chronic
obstructive pulmonary disease. Am J Respir Crit Care Med.
2005;171(9):972–977. doi:10.1164/rccm.200407-855OC
2. Minakata Y, Sugino A, Kanda M, et al. Reduced level of physical
activity in Japanese patients with chronic obstructive pulmonary disease.
Respir Investig. 2014;52(1):41–48. doi:10.1016/j.resinv.2013.06.002
3. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular
physical activity reduces hospital admission and mortality in chronic
obstructive pulmonary disease: a population based cohort study.
Thorax. 2006;61(9):772–778. doi:10.1136/thx.2006.060145
4. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest
predictor of all-cause mortality in patients with COPD: a prospective
cohort study. Chest. 2011;140(2):331–342. doi:10.1378/chest.10-2521
5. Garcia-Rio F, Rojo B, Casitas R, et al. Prognostic value of the
objective measurement of daily physical activity in patients with
COPD. Chest. 2012;142(2):338–346. doi:10.1378/chest.11-2014
6. Watz H, Krippner F, Kirsten A, Magnussen H, Vogelmeier C.
Indacaterol improves lung hyperinflation and physical activity in
patients with moderate chronic obstructive pulmonary disease–a ran-
domized, multicenter, double-blind, placebo-controlled study. BMC
Pulm Med. 2014;14:158. doi:10.1186/1471-2466-14-158
7. Beeh KM, Watz H, Puente-Maestu L, et al. Aclidinium improves exer-
cise endurance, dyspnea, lung hyperinflation, and physical activity in
patients with COPD: a randomized, placebo-controlled, crossover trial.
BMC Pulm Med. 2014;14(1):209. doi:10.1186/1471-2466-14-209
8. Minakata Y, Morishita Y, Ichikawa T, et al. Effects of pharmacologic
treatment based on airflow limitation and breathlessness on daily
physical activity in patients with chronic obstructive pulmonary dis-
ease. Int J Chron Obstruct Pulmon Dis. 2015;10:1275–1282.
doi:10.2147/COPD.S84134
9. O’Donnell DE, Casaburi R, Vincken W, et al. Effect of indacaterol on
exercise endurance and lung hyperinflation in COPD. Respir Med.
2011;105(7):1030–1036. doi:10.1016/j.rmed.2011.03.014
10. Troosters T, Sciurba FC, Decramer M, et al. Tiotropium in patients
with moderate COPD naive to maintenance therapy: a randomised
placebo-controlled trial. NPJ Prim Care Respir Med. 2014;24:14003.
doi:10.1038/npjpcrm.2014.3
11. Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient
multidisciplinary pulmonary rehabilitation: a randomised controlled trial.
Lancet. 2000;355(9201):362–368. doi:10.1016/s0140-6736(99)07042-7
12. Pitta F, Troosters T, Probst VS, Langer D, Decramer M, Gosselink R.
Are patients with COPD more active after pulmonary rehabilitation?
Chest. 2008;134(2):273–280. doi:10.1378/chest.07-2655
13. Mador MJ, Patel AN, Nadler J. Effects of pulmonary rehabilitation
on activity levels in patients with chronic obstructive pulmonary
disease. J Cardiopulm Rehabil Prev. 2011;31(1):52–59. doi:10.
1097/HCR.0b013e3181ebf2ef
14. Mendoza L, Horta P, Espinoza J, et al. Pedometers to enhance
physical activity in COPD: a randomised controlled trial. Eur
Respir J. 2015;45(2):347–354. doi:10.1183/09031936.00084514
15. Shioya T, Sato S, Iwakura M, et al. Improvement of physical activity
in chronic obstructive pulmonary disease by pulmonary rehabilitation
and pharmacological treatment. Respir Investig. 2018;56(4):292–306.
doi:10.1016/j.resinv.2018.05.002
16. AltenburgWA,TenHackenNH,Bossenbroek L,KerstjensHA, deGreef
MH, Wempe JB. Short- and long-term effects of a physical activity
counselling programme in COPD: a randomized controlled trial.
Respir Med. 2015;109(1):112–121. doi:10.1016/j.rmed.2014.10.020
17. Nelson ME, Rejeski WJ, Blair SN, et al. Physical activity and public
health in older adults: recommendation from the American college of
sports medicine and the American heart association. Circulation.
2007;116(9):1094–1105. doi:10.1161/CIRCULATIONAHA.107.185650
18. Watz H, Pitta F, Rochester CL, et al. An official European
Respiratory Society statement on physical activity in COPD. Eur
Respir J. 2014;44(6):1521–1537. doi:10.1183/09031936.00046814
19. Sugino A, Minakata Y, Kanda M, et al. Validation of a compact
motion sensor for the measurement of physical activity in patients
with chronic obstructive pulmonary disease. Respiration. 2012;83
(4):300–307. doi:10.1159/000330046
20. Miyamoto S, Minakata Y, Azuma Y, et al. Verification of a motion
sensor for evaluating physical activity in COPD patients. Can Respir
J. 2018;2018:8343705. doi:10.1155/2018/8343705
21. Rabinovich RA, Louvaris Z, Raste Y, et al. Validity of physical
activity monitors during daily life in patients with COPD. Eur
Respir J. 2013;42(5):1205–1215. doi:10.1183/09031936.00134312
22. Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in
patients with COPD. Eur Respir J. 2009;33(2):262–272. doi:10.1183/
09031936.00024608
23. Byrom B, Rowe DA. Measuring free-living physical activity in
COPD patients: deriving methodology standards for clinical trials
through a review of research studies. Contemp Clin Trials.
2016;47:172–184. doi:10.1016/j.cct.2016.01.006
24. Hernandes NA, Teixeira Dde C, Probst VS, Brunetto AF, Ramos EM,
Pitta F. Profile of the level of physical activity in the daily lives of
patients with COPD in Brazil. J Bras Pneumol. 2009;35(10):949–
956. doi:10.1590/s1806-37132009001000002
25. Steele BG, Holt L, Belza B, Ferris S, Lakshminaryan S, Buchner DM.
Quantitating physical activity in COPD using a triaxial accelerometer.
Chest. 2000;117(5):1359–1367. doi:10.1378/chest.117.5.1359
26. Waschki B, Spruit MA, Watz H, et al. Physical activity monitoring in
COPD: compliance and associations with clinical characteristics in a
multicenter study. Respir Med. 2012;106(4):522–530. doi:10.1016/j.
rmed.2011.10.022
27. Walker PP, Burnett A, Flavahan PW, Calverley PM. Lower limb
activity and its determinants in COPD. Thorax. 2008;63(8):683–
689. doi:10.1136/thx.2007.087130
28. Hayata A, Minakata Y, Matsunaga K, Nakanishi M, Yamamoto N.
Differences in physical activity according to mMRC grade in patients
with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2203–2208.
doi:10.2147/COPD.S109694
29. Saunders T, Campbell N, Jason T, et al. Objectively measured steps/
day in patients with chronic obstructive pulmonary disease: a sys-
tematic review and meta-analysis. J Phys Act Health. 2016;13
(11):1275–1283. doi:10.1123/jpah.2016-0087
30. Lahaije AJ, van Helvoort HA, Dekhuijzen PN, Vercoulen JH, Heijdra
YF. Resting and ADL-induced dynamic hyperinflation explain phy-
sical inactivity in COPD better than FEV1. Respir Med. 2013;107
(6):834–840. doi:10.1016/j.rmed.2013.02.017
31. Althoff T, Sosic R, Hicks JL, King AC, Delp SL, Leskovec J. Large-
scale physical activity data reveal worldwide activity inequality.
Nature. 2017;547(7663):336–339. doi:10.1038/nature23018
32. National Institute of Health and Nutrition. The National Health and
Nutrition Survey in Japan 2017. Tokyo, Japan, 2018 (in Japanese).
Available from: https://www.mhlw.go.jp/content/000451758.pdf.
Accessed January 7, 2019
33. National Institute of Health and Nutrition. Table 5, (2) Physical activity
and exercise in List of Targets, Health Japan 21 (the second term),
Tokyo, Japan. Available from: https://www.nibiohn.go.jp/eiken/kenkou
nippon21/en/kenkounippon21/mokuhyou05.html. Accessed January 7,
2019.
34. Hataji O, Naito M, Ito K, Watanabe F, Gabazza EC, Taguchi O.
Indacaterol improves daily physical activity in patients with chronic
obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis.
2013;8:1–5. doi:10.2147/COPD.S38548
35. Portal Site of Official Statistics of Japan (S-Stat). Patient Survey
2017 (in Japanese), Tokyo, Japan, 2019. Available from: https://
www.e-stat.go.jp/dbview?sid=0003318584. Accessed January 7,
2019.
Nakanishi et al Dovepress
submit your manuscript | www.dovepress.com
DovePress


















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
36. Landis SH, Muellerova H, Mannino DM, et al. Continuing to con-
front COPD international patient survey: methods, COPD prevalence,
and disease burden in 2012–2013. Int J Chron Obstruct Pulmon Dis.
2014;9:597–611. doi:10.2147/COPD.S61854
37. Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan: the
nippon COPD epidemiology study. Respirology. 2004;9(4):458–465.
doi:10.1111/j.1440-1843.2004.00637.x
38. Matsumoto K, Seki N, Fukuyama S, et al. Prevalence of asthma with
airflow limitation, COPD, and COPD with variable airflow limitation
in older subjects in a general Japanese population: the Hisayama study.
Respir Investig. 2015;53(1):22–29. doi:10.1016/j.resinv.2014.08.002
39. Ishii T, Nishimura M, Akimoto A, James MH, Jones P.
Understanding low COPD exacerbation rates in Japan: a review and
comparison with other countries. Int J Chron Obstruct Pulmon Dis.
2018;13:3459–3471. doi:10.2147/COPD.S165187
40. Donaire-Gonzalez D, Gimeno-Santos E, Balcells E, et al. Benefits
of physical activity on COPD hospitalisation depend on intensity.
Eur Respir J. 2015;46(5):1281–1289. doi:10.1183/13993003.016
99-2014
Dovepress Nakanishi et al




















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Supplementary materials
Subjects and methods
Stable outpatients with COPD were recreated at NHO
Wakayama Hospital. COPD was diagnosed as a post-
bronchodilator FEV1/FVC <0.7. AM and HJA-750C
were worn on the waist of patients at the same time
for 1 week. The step counts measured by both devices
were compared. Written informed consent was obtained
from all patients. This study has been approved by the
ethics committee of NHO Wakayama Hospital
(approved number 8, March 20, 2017) and has been
registered with the University Hospital Medical
Information Network (UMIN000016363, January 28,
2015).
Table S1 Characteristics of patients
Age (years) 76.6 (6.9)





GOLD stage (I/II/III/IV), n 1/5/6/0
mMRC scale (0/1/2/3/4), n 1/4/1/6/0
Pulmonary function
IC (L) 1.88 (0.41)
FVC (L) 2.78 (0.60)
FVC % of predicted (%) 86.1 (20.4)
FEV1 (L) 1.43 (0.37)
FEV1/FVC (%) 51.7 (9.2)
FEV1% of predicted (%) 57.6 (18.6)
Note: Data are presented as mean (SD).
Abbreviations: M, male; F, female; curr, current smoker; ex, ex-smoker; non, non-smoker; BMI, Body Mass Index; GOLD, Global Initiative for Chronic Obstructive Lung






























Figure S1 Correlation between step counts by AM and HJA-750C. (A) scatter plot, r=0.990 P<0.0001 and (B) Bland–Altman plot. There was no systematic bias. (mean of
difference 95% CI: −30.23 to 131.43, limit of agreement: −417.6 to 518.9). Broken lines indicate mean difference 95% CI and dotted lines indicate limit of agreement.
Abbreviations: HJA-750C, Active Style Pro HJA-750C; AM, Actimarker.
Nakanishi et al Dovepress
submit your manuscript | www.dovepress.com
DovePress


















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Chronic Obstructive Pulmonary Disease Dovepress
Publish your work in this journal
The International Journal of COPD is an international, peer-reviewed
journal of therapeutics and pharmacology focusing on concise rapid
reporting of clinical studies and reviews in COPD. Special focus is
given to the pathophysiological processes underlying the disease, inter-
vention programs, patient focused education, and self management
protocols. This journal is indexed on PubMed Central, MedLine
and CAS. The manuscript management system is completely online
and includes a very quick and fair peer-review system, which is
all easy to use. Visit http://www.dovepress.com/testimonials.php to
read real quotes from published authors.
Submit your manuscript here: https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
Dovepress Nakanishi et al




















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
